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To further dissect the genetic architecture of colorectal cancer (CRC), we performed 292 
whole-genome sequencing of 1,439 cases and 720 controls, imputed discovered sequence 293 
variants and Haplotype Reference Consortium panel variants into genome-wide association 294 
study data, and tested for association in 34,869 cases and 29,051 controls. Findings were 295 
followed up in an additional 23,262 cases and 38,296 controls. We discovered a strongly 296 
protective 0.3% frequency variant signal at CHD1. In a combined meta-analysis of 125,478 297 
individuals, we identified 40 new independent signals at P<5×10-8, bringing the number of 298 
known independent signals for CRC to approximately 100. New signals implicate lower-299 
frequency variants, Krüppel-like factors, Hedgehog signaling, Hippo-YAP signaling, long 300 
noncoding RNAs, somatic drivers, and support a role of immune function. Heritability 301 
analyses suggest that CRC risk is highly polygenic, and larger, more comprehensive studies 302 
enabling rare variant analysis will improve understanding of underlying biology, and 303 
impact personalized screening strategies and drug development. 304 
 305 
Colorectal cancer (CRC) is the fourth leading cancer-related cause of death worldwide1 and 306 
presents a major public health burden. Up to 35% of inter-individual variability in CRC risk has 307 
been attributed to genetic factors2,3. Family-based studies have identified rare high-penetrance 308 
mutations in at least a dozen genes but, collectively, these account for only a small fraction of 309 
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familial risk4. Over the past decade, genome-wide association studies (GWAS) for sporadic 310 
CRC, which constitutes the majority of cases, have identified approximately 60 association 311 
signals at over 50 loci5–22. Yet, most of the genetic factors contributing to CRC risk remain 312 
undefined. This severely hampers our understanding of biological processes underlying CRC. It 313 
also limits CRC precision prevention, including individualized preventive screening 314 
recommendations and development of cancer prevention drugs. The contribution of rare 315 
variation to sporadic CRC is particularly poorly understood. 316 
 317 
To expand the catalog of CRC risk loci and improve our understanding of rare variants, genes, 318 
and pathways influencing sporadic CRC risk, and risk prediction, we performed the largest and 319 
most comprehensive whole-genome sequencing (WGS) study and GWAS meta-analysis for 320 
CRC to date, combining data from three consortia: the Genetics and Epidemiology of Colorectal 321 
Cancer Consortium (GECCO), the Colorectal Cancer Transdisciplinary Study (CORECT), and 322 
the Colon Cancer Family Registry (CCFR). Our study almost doubles the number of individuals 323 
analyzed, incorporating GWAS results from >125,000 individuals, and substantially expands and 324 
strengthens our understanding of biological processes underlying CRC risk. 325 
 326 
RESULTS 327 
Study Overview 328 
We performed WGS of 1,439 CRC cases and 720 controls of European ancestry at low coverage 329 
(3.8-8.6×). We detected, called, and estimated haplotype phase for 31.8 million genetic variants, 330 
including 1.7 million short insertion-deletion variants (indels) (Online Methods). These data 331 
include many rare variants not studied by GWAS. Based on other large-scale WGS studies 332 
employing a similar design, we expected to have near-complete ascertainment of single 333 
nucleotide variants (SNVs) with minor allele count (MAC) greater than five (minor allele 334 
frequency (MAF) >0.1%), and high accuracy at heterozygous genotypes23,24. We tested 14.4 335 
million variants with MAC ≥5 for CRC association using logistic regression (Online Methods) 336 
but did not find any significant associations. To increase power to detect associations with rare 337 
and low-frequency variants of modest effect, we imputed variants from the sequencing 338 
experiment into 34,869 cases and 29,051 controls of predominantly European (91.7%) and East 339 
Asian ancestry (8.3%) from 30 existing GWAS studies (Online Methods and Supplementary 340 
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Table 1). By design, two thirds of sequenced individuals were CRC cases, thereby enriching the 341 
panel for rare or low-frequency alleles that increase CRC risk. We contributed our sequencing 342 
data to the Haplotype Reference Consortium (HRC)25 and imputed the 30 existing GWAS 343 
studies to the HRC panel, which comprises haplotypes for 32,488 individuals. Results of these 344 
GWAS meta-analyses (referred to as Stage 1 meta-analysis; Online Methods) informed the 345 
design of a custom Illumina array comprising the OncoArray, a custom array to identify cancer 346 
risk loci26, and 15,802 additional variants selected based on Stage 1 meta-analysis results. We 347 
genotyped 12,007 cases and 12,000 controls of European ancestry with this custom array, and 348 
combined them with an additional 11,255 cases and 26,296 controls with GWAS data, resulting 349 
in a Stage 2 meta-analysis of 23,262 CRC cases and 38,296 controls (Online Methods, 350 
Supplementary Fig. 1, and Supplementary Table 1). Next, we performed a combined (Stage 1 351 
+ Stage 2) meta-analysis of up to 58,131 cases and 67,347 controls. This meta-analysis was 352 
based on the HRC-panel-imputed data because, given its large size, this panel results in superior 353 
imputation quality and enables accurate imputation of variants with MAFs as low as 0.1%25. 354 
Here, we report new association signals discovered through our custom genotyping experiment 355 
and replicating in Stage 2 at the Bonferroni significance threshold of P < 7.8×10-6 (Online 356 
Methods), as well as distinct association signals passing the genome-wide significance (GWS) 357 
threshold of P < 5×10-8 in the combined meta-analysis of up to 125,478 individuals. 358 
 359 
CRC risk loci 360 
In the combined meta-analysis, we identified 30 new CRC risk loci reaching GWS and >500kb 361 
away from previously reported CRC risk variants (Table 1; Supplementary Fig. 2 and 3). 362 
Twenty-two of these were represented on our custom genotyping panel, either by the lead variant 363 
(15 loci) or by a variant in linkage disequilibrium (LD) (7 loci; r2>0.7). Of these 22 variants, 364 
eight attained the Bonferroni significance threshold in the Stage 2 meta-analysis (Table 1). 365 
 366 
Among these eight loci is the first rare variant signal identified for sporadic CRC, involving five 367 
0.3% frequency variants at 5q21.1, near genes CHD1 and RGMB. SNP rs145364999, intronic to 368 
CHD1, had high quality genotyping (Supplementary Fig. 4). The variant was well imputed in 369 
the remaining sample sets (imputation quality r2 ranged from 0.66 to 0.87; Supplementary 370 
Table 2) and there was no evidence of heterogeneity of effects (heterogeneity P=0.63; 371 
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Supplementary Table 2). The rare allele confers a strong protective effect (allelic odds ratio 372 
(OR)=0.52 in Stage 2; 95% confidence interval (CI)=0.40-0.68). Chromatin remodeling factor 373 
CHD1 provides an especially plausible candidate and has been shown to be a synthetically-374 
essential gene27 that is occasionally deleted in some cancers, but always retained in PTEN-375 
deficient cancers28. The resulting mutually exclusive deletion pattern of CHD1 and PTEN has 376 
been observed in prostate, breast, and CRC TCGA data28. We hypothesize that the rare allele 377 
confers a protective effect through lowering CHD1 expression, which is required for nuclear 378 
factor-κβ (NF-κβ) pathway activation and growth in cancer cells driven by loss of the tumor 379 
suppressor PTEN28. However, we cannot rule out involvement of nearby candidate gene RGMB 380 
that encodes a co-receptor for bone morphogenetic proteins BMP2 and BMP4, both of which are 381 
linked to CRC risk through GWAS9,11. Additionally, RGMB has been shown to bind to PD-L229, 382 
a known ligand of PD-1, an immune checkpoint blockade inhibitor targeted by cancer 383 
immunotherapy30. 384 
 385 
The vast majority of new association signals involve common variants. We found associations 386 
near strong candidate genes for CRC risk in pathways or gene families not previously implicated 387 
by GWAS. Locus 13q22.1, represented by lead SNP rs78341008 (MAF 7.2%; P=3.2×10-10), is 388 
near KLF5, a known CRC oncogene that can be activated by somatic hotspot mutations or super-389 
enhancer duplications31,32. KLF5 encodes transcription factor Krüppel-like factor 5 (KLF5), 390 
which promotes cell proliferation and is highly expressed in intestinal crypt stem cells. We also 391 
found an association at 19p13.11, near KLF2. KLF2 expression in endothelial cells is critical for 392 
normal blood vessel function33,34. Down-regulated KLF2 expression in colon tumor tissues 393 
contributes to structurally and functionally abnormal tumor blood vessels, resulting in impaired 394 
blood flow and hypoxia in tumors35. Another locus at 9q31.1 is near LPAR1, which encodes a 395 
receptor for lysophosphatidic acid (LPA). LPA-induced expression of hypoxia-inducible factor 1 396 
(HIF-1α), a key regulator of cellular adaptation to hypoxia and tumorigenesis, depends on 397 
KLF536. Additionally, LPA activates multiple signaling pathways and stimulates proliferation of 398 
colon cancer cells by activation of KLF537. Another locus (7p13) is near SNHG15, encoding a 399 
long non-coding RNA (lncRNA) that epigenetically represses KLF2 to promote pancreatic 400 
cancer proliferation38. 401 
 402 
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We found two loci near members of the Hedgehog (Hh) signaling pathway. Aberrant activation 403 
of this pathway, caused by somatic mutations or changes in expression, can drive tumorigenesis 404 
in many tumors39. Notably, downregulated stromal cell Hh signaling reportedly accelerates 405 
colonic tumorigenesis in mice40. Locus 3q13.2, represented by low-frequency lead SNP 406 
rs72942485 (MAF 2.2%; P=2.1×10-8), overlaps BOC, encoding a Hh coreceptor molecule. In 407 
medulloblastoma, upregulated BOC promotes Hh-driven tumor progression through Cyclin D1-408 
induced DNA damage41. In pancreatic cancer, a complex role for stromal BOC expression in 409 
tumorigenesis and angiogenesis has been reported42. Locus 4q31.21 is near HHIP, encoding an 410 
inhibitor of Hh signaling. Of note, the Hh signaling pathway was also significantly enriched in 411 
our pathway analysis (described below). 412 
 413 
Locus 11q22.1 is near YAP1, which encodes a critical downstream regulatory target in the Hippo 414 
signaling pathway that is gaining recognition as a pivotal player in organ size control and 415 
tumorigenesis43. YAP1 is highly expressed in intestinal crypt stem cells, and in transgenic mice, 416 
overexpression resulted in severe intestinal dysplasia and loss of differentiated cell types44, 417 
reminiscent of phenotypes observed in mice and humans with deleterious germline APC 418 
mutations. Further, Hypoxia-inducible factor 2α (HIF-2α) promotes colon cancer growth by up-419 
regulating YAP1 activity45. 420 
 421 
We provide further evidence for a link between immune function and CRC pathogenesis, and 422 
implicate the major histocompatibility complex (MHC) in CRC risk. We identified a locus near 423 
genes HLA-DRB1/HLA-DQA1, which is associated with immune-mediated diseases46. 424 
 425 
We identified two new loci near known tumor suppressor genes. Locus 4q24 is near TET2, a 426 
chromatin-remodeling gene frequently somatically mutated in multiple cancers, including colon 427 
cancer47, and overlapping GWAS signals for multiple other cancers48–50. The CDKN2B-428 
CDKN2A-ANRIL locus at 9p21.3 is a well-established hot spot of pleiotropic GWAS 429 
associations for many complex diseases including coronary artery disease51, type 2 diabetes52, 430 
and cancers50,53,54–56. Interestingly, lead variant rs1537372 is in high LD (r2=0.82) with variants 431 
associated with coronary artery disease51 and endometriosis57, but not with the other cancer-432 
associated variants. CDKN2A/B encode cyclin-dependent kinase inhibitors that regulate the cell 433 
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cycle. CDKN2A is one of the most commonly inactivated genes in cancer, and is a high 434 
penetrance gene for melanoma58,59. CDKN2B activation is tightly controlled by the cytokine 435 
TGF-β, further linking this signaling pathway with CRC tumorigenesis60. 436 
 437 
Our findings implicate genes in pathways with established roles in CRC pathogenesis. We 438 
identified loci at SMAD3 and SMAD9, members of the TGF-β signaling pathway that includes 439 
genes linked to familial CRC syndromes (e.g., SMAD4 and BMPR1A) and several GWAS-440 
implicated genes (e.g., SMAD7, BMP2, BMP4)61. We identified another locus near TGF-β 441 
Receptor 1 (TGFBR1). Nearby gene GALNT12 reportedly harbors inactivating germline and 442 
somatic mutations in human colon cancers62 and, therefore, could also be the regulated effector 443 
gene. We identified a locus at 14q23.1 near DACT1, a member of the Wnt-β-catenin pathway 444 
with genes previously linked to familial CRC syndromes (APC63), and several GWAS-implicated 445 
genes (e.g., CTNNB118 and TCF7L217 ). Genes related to telomere biology were linked by other 446 
GWAS: TERC10 and TERT22, encoding the RNA and protein subunit of telomerase respectively, 447 
and FEN117, involved in telomere stability64. A new locus at 20q13.33 harbors another gene 448 
related to telomere biology, RTEL1. This gene is involved in DNA double-strand break repair, 449 
and overlaps GWAS signals for cancers55,65 and inflammation-related phenotypes, including 450 
inflammatory bowel disease66 and atopic dermatitis67. 451 
 452 
Of 61 signals at 56 loci previously associated with CRC at GWS, 42 showed association 453 
evidence at P < 5×10-8 in the combined meta-analysis, and 55 at P < 0.05 in the independent 454 
Stage 2 meta-analysis (Supplementary Table 3). Of note, the association of rs755229494 at 455 
locus 5q22.2 (P=2.1×10-12) was driven by studies with predominantly Ashkenazi Jewish ancestry 456 
and this SNP is in perfect LD with known missense SNP rs1801155 in the APC gene (I1307K), 457 
the minor allele of which is enriched in this population (MAF 6%), but rare in other 458 
populations68,69. 459 
 460 
Delineating distinct association signals at CRC risk loci 461 
To identify additional independent association signals at known or new CRC risk loci, we 462 
conducted conditional analysis using individual-level data of 125,478 participants (Online 463 
Methods). At nine loci we observed 10 new independent association signals that attained PJ 464 
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<5×10-8 in a joint multiple-variant analysis (Table 2; Supplementary Table 4; Supplementary 465 
Fig. 5). Because this analysis focused on <5% of the genome, we also report signals at PJ <1×10-466 
5 in Supplementary Table 5. At 22 loci, we observed 25 new suggestive associations with PJ 467 
<1×10-5. 468 
 469 
At 11q13.4, near POLD3 and CHRDL2, we identified a new low-frequency variant (lead SNP 470 
rs61389091, MAF 3.94%) separated by a recombination hotspot from the known common 471 
variant signal12 (LD r2 between lead SNPs <0.01). At 5p15.33, we identified another lower-472 
frequency variant association (lead SNP rs78368589, MAF 5.97%), which was independent from 473 
the previously reported common variant signal 56kb away near TERT and CLPTM1L (LD r2 with 474 
lead SNP rs2735940 <0.01)22. Variants in this region were linked to many cancer types, 475 
including lung, prostate, breast, and ovarian cancer70. 476 
 477 
The remaining eight new signals involved common variants. At new locus 2q33.1, near genes 478 
PLCL1 and SATB2, two statistically independent associations (LD r2 between two lead SNPs 479 
<0.01) are separated by a recombination hotspot (Supplementary Fig. 5). In the MHC region, 480 
we identified a conditionally independent signal near genes involved in NF-κβ signaling, 481 
including the gene encoding tumor necrosis factor-α, genes for the stress-signaling proteins 482 
MICA/MICB, and HLA-B. Locus 20p12.3, near BMP2, harbored four distinct association signals 483 
(Figure 1), two of which were reported previously10,11 (Supplementary Table 5). All four SNPs 484 
selected in the model were in pairwise linkage equilibrium (maximum LD r2 = 0.039, between 485 
rs189583 and rs994308). Our conditional analysis further confirmed that the signal ~1-Mb 486 
centromeric of BMP2, near gene HAO1, is independent. At 8q24.21 near MYC, the locus 487 
showing the second strongest statistical evidence of association in the combined meta-analysis 488 
(lead SNP rs6983267; P = 3.4×10-64), we identified a second independent signal (lead SNP 489 
rs4313119, PJ = 2.1×10-9; LD r2 with rs6983267 <0.001). At the recently reported locus 490 
5p13.122, near the non-coding RNA gene LINC00603, we identified an additional signal (lead 491 
SNP rs7708610) that was partly masked by the reported signal in the single-variant analysis due 492 
to the negative correlation between rs7708610 and rs12514517 (r = −0.18; r2 = 0.03). This 493 
caused significance for both SNPs to increase markedly when fitted jointly (rs7708610, 494 
unconditional P = 1.5×10-5 and PJ = 3.8×10-9). At 12p13.32 near CCND2, we identified a new 495 
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signal (lead SNP rs3217874, PJ = 2.4×10-9) and confirmed two previously associated signals13–15 496 
(Supplementary Text). At the GREM1 locus on 15q13.3, two independent signals were 497 
previously described11. Our analyses suggest that this locus harbors three signals. A new signal 498 
represented by SNP rs17816465 is conditionally independent from the other two signals (PJ = 499 
1.4×10-10, conditioned on rs2293581 and rs12708491; LD with conditioning SNPs r2<0.01; 500 
Supplementary Text). 501 
 502 
Additionally, signals with PJ values approaching GWS were observed at new locus 3q13.2 near 503 
BOC (rs13086367, unconditional P = 6.7×10-8, PJ = 6.9×10-8, MAF=47.4%), 96kb from the low-504 
frequency signal represented by rs72942485 (unconditional P = 2.1×10-8, PJ = 1.3×10-8, 505 
MAF=2.2%); at known locus 10q22.3 near ZMIZ1 (rs1250567, unconditional P = 3.1×10-8, PJ = 506 
7.2×10-8, MAF=45.1%); and at new locus 13q22.1 near KLF5 (rs45597035, unconditional P = 507 
2.7×10-9, PJ = 8.1×10-8, MAF=34.4%) (Supplementary Table 5). Furthermore, we clarify 508 
previously reported independent association signals (Supplementary Text). 509 
 510 
Associations of CRC risk variants with other traits 511 
Nineteen of the GWS association signals for CRC were in high LD (r2>0.7) with at least one 512 
SNP in the NHGRI-EBI GWAS Catalog46 that has significant association in GWAS of other 513 
traits. Notable overlap included SNPs associated with other cancers, immune-related traits (e.g., 514 
tonsillectomy, inflammatory bowel disease, and circulating white blood cell traits), obesity traits, 515 
blood pressure, and other cardiometabolic traits (Supplementary Table 6). 516 
 517 
Mechanisms underlying CRC association signals 518 
To further localize variants driving the 40 newly identified signals, we used association evidence 519 
to define credible sets of variants that are 99% likely to contain the causal variant (Online 520 
Methods). The 99% credible set size for new loci ranged from one (17p12) to 93 (2q33.1). For 521 
11 distinct association signals, the set included ten or fewer variants (Supplementary Table 7). 522 
At locus 17p12, we narrowed the candidate variant to rs1078643, located in exon 1 of the 523 
lncRNA LINC00675 that is primarily expressed in gastrointestinal tissues. Small credible sets 524 
were observed for locus 4q31.21 (two variants, indexed by synonymous SNP rs11727676 in 525 
HHIP), and signals at known loci near GREM1 (one variant) and CCND2 (two variants). 526 
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 527 
We performed functional annotation of credible set variants to nominate putative causal variants. 528 
Eight sets contained coding variants but only the synonymous SNP in HHIP had a high posterior 529 
probability of driving the association (Supplementary Table 8). Next, we examined overlap of 530 
credible sets with regulatory genomic annotations from 51 existing CRC-relevant datasets to 531 
examine non-coding functions (Online Methods). Also, to better refine regulatory elements in 532 
active enhancers, we performed ATAC-seq to measure chromatin accessibility in four colonic 533 
crypts and used resulting data to annotate GWAS signals. 534 
 535 
Of the 40 sets, 36 overlapped with active enhancers identified by histone mark H3K27ac 536 
measured in normal colonic crypt epithelium, CRC cell lines, or CRC tissue (Supplementary 537 
Table 8; Supplementary Fig. 6). Twenty of these 36 overlapped with super-enhancers. Notably, 538 
when compared with epigenomics data from normal colonic crypt epithelium, all 36 sets 539 
overlapped enhancers with gained or lost activity in one or more CRC specimens. Eleven of 540 
these sets overlapped enhancers recurrently gained or lost in >20 CRC cell lines. 541 
 542 
The locus at GWAS hot spot 9p21 overlaps a super-enhancer, and the credible set is entirely 543 
intronic to ANRIL, alias CDKN2B-AS1. The Genotype-Tissue Expression (GTEx) data show that 544 
the antisense lncRNA ANRIL is exclusively expressed in transverse colon and small intestine. 545 
Interestingly, ANRIL recruits SUZ12 and EHZ2 to epigenetically silence tumor suppressor genes 546 
CDKN2A/B71. 547 
 548 
Noncoding somatic driver mutations or focal amplifications have been reported in regions 549 
regulating expression of MYC72, TERT73, and KLF531, now implicated by GWAS for CRC. We 550 
checked whether GWAS-identified association signals co-localize with these regions and found 551 
that the KLF5 signal overlaps the somatically amplified super-enhancer flanked by KLF5 and 552 
KLF12 (Figure 2). Also, the previously reported signal in the TERT promotor region22 overlaps 553 
with the recurrent somatically mutated region in multiple cancers73. 554 
 555 
To test whether CRC associations are non-randomly distributed across genomic features, we 556 
used GARFIELD74. Focusing on DNase I hypersensitive site (DHS) peaks that identify open 557 
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chromatin, we observed significant enrichment across many cell types, particularly fetal tissues, 558 
with strongest enrichment observed in fetal gastrointestinal tissues, CD20+ primary cells (B 559 
cells), and embryonic stem cells (Supplementary Fig. 7; Supplementary Table 9). 560 
 561 
We used MAGENTA75 to identify pathways or gene sets enriched for associations with CRC, 562 
assessing two gene P-value cutoffs: 95th and 75th percentiles. At the 75th percentile, we 563 
observed enrichment of multiple KEGG cancer pathways at a false discovery rate (FDR) of 0.05. 564 
This was not observed for the 95th percentile cutoff and suggests that many more loci that are 565 
shared with other cancer types remain to be identified in larger studies. Using the 75th (95th) 566 
percentile cutoff, at FDR 0.05 and 0.20, we found enrichment of 7 (5) and 53 (24) gene sets, 567 
respectively. Established pathways related to TGF-β/SMAD and BMP signaling were among the 568 
top enriched pathways. Other notable enriched pathways included Hedgehog signaling, basal cell 569 
carcinoma, melanogenesis, cell cycle, S phase, and telomere maintenance (Supplementary 570 
Table 10). 571 
 572 
Polygenicity of colorectal cancer and contribution of rare variants 573 
To estimate the contribution of rare variants (MAF ≤1%) to CRC heritability, we used the LD- 574 
and MAF-stratified component GREML (GREML-LDMS) method implemented in GCTA76 575 
(Online Methods). Assuming a lifetime risk of 4.3%, we estimated that all imputed autosomal 576 
variants explain 21.6% (95% CI=17.5-25.7%) of the variation in liability for CRC, with almost 577 
half of this contributed by rare variants (ℎ"#= 9.7%, 95% CI=6.2-13.3%; likelihood ratio test 578 
P=0.003); the estimated liability-scale heritability for variants with MAF >1% is 11.8% (95% 579 
CI=8.9-14.7%). Our overall estimate falls within the range of heritability reported by large twin 580 
studies2. Because heritability estimates for rare variants are sensitive to potential biases due to 581 
technical effects or population stratification77 and the contribution of rare variants is probably 582 
underestimated due to limitations of genotype imputation, results should be interpreted with 583 
caution. Overall, findings suggest that missing heritability is not large, but that many rare and 584 
common variants have yet to be identified. 585 
 586 
Familial relative risk explained by GWAS-identified variants 587 
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Adjusting for winner’s curse78, the familial relative risk (RR) to first-degree relatives (λ0) 588 
attributable to GWAS-identified variants rose from 1.072 for the 55 previously described 589 
autosomal risk variants that showed evidence for replication at P <0.05, to 1.092 after inclusion 590 
of 40 new signals, and increased further to 1.098 when we included 25 suggestive association 591 
signals reported in Supplementary Table 5 (Online Methods). Assuming a λ0 of 2.2, the 55 592 
established signals account for 8.8% of familial RR explained (95% CI: 8.1-9.4). Established 593 
signals combined with 40 newly discovered signals account for 11.2% (95% CI: 10.5-12.0), and 594 
adding 25 suggestive signals increases this to 11.9% (95% CI: 11.1-12.7). 595 
 596 
Implications for stratified screening prevention 597 
We demonstrate how using a polygenic risk score (PRS) derived from 95 independent 598 
association signals could impact clinical guidelines for preventive screening. The difference in 599 
recommended starting age for screening for those in the highest 1% (and 10%) percentiles of risk 600 
compared with lowest percentiles is 18 years (and 10 years) for men, and 24 years (and 12 years) 601 
for women (Figure 3; Online Methods). Supplementary Table 11 gives risk allele frequency 602 
(RAF) estimates in different populations for variants included in the PRS. As expected, RAFs 603 
vary across populations. Furthermore, differences in LD between tagging and true causal variants 604 
across populations can result in less prediction accuracy and subsequent lower predictive power 605 
of the PRS in non-European populations. Accordingly, it will be important to develop ancestry-606 
specific PRSs that incorporate detailed fine-mapping results for each GWAS signal. 607 
 608 
DISCUSSION 609 
To further define the genetic architecture of sporadic CRC, we performed low-coverage WGS 610 
and imputation into a large set of GWAS data. We discovered 40 new CRC signals and 611 
replicated 55 previously reported signals. We found the first rare variant signal for sporadic 612 
CRC, which represents the strongest protective rare allelic effect identified to date. Our analyses 613 
highlight new genes and pathways contributing to underlying CRC risk and suggest roles for 614 
Krüppel-like factors, Hedgehog signaling, Hippo-YAP signaling, and immune function. Multiple 615 
loci provide new evidence for an important role of lncRNAs in CRC tumorigenesis79. Functional 616 
genomic annotations support that most sporadic CRC genetic risk lies in non-coding genomic 617 
regions. We further show how newly discovered variants can lead to improved risk prediction. 618 
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 619 
This study underscores the critical importance of large-scale GWAS collaboration. While 620 
discovery of the rare variant signal was only possible through increased coverage and improved 621 
imputation accuracy enabled by imputation panels, sample size was pivotal for discovery of new 622 
CRC loci. Results suggest that CRC exhibits a highly polygenic architecture, much of which 623 
remains undefined. This also suggests that continued GWAS efforts, together with increasingly 624 
comprehensive imputation panels that allow for improved low-frequency and rare genetic variant 625 
imputation, will uncover more CRC risk variants. In addition, to investigate sites that are not 626 
imputable, large-scale deep sequencing will be needed. Importantly, the prevailing European bias 627 
in CRC GWAS limits the generalizability of findings and the application of PRSs in non-628 
European (especially African) populations80. Therefore, a broader representation of ancestries in 629 
CRC GWAS is necessary. 630 
 631 
Studies of somatic genomic alterations in cancer have mostly focused on the coding genome and 632 
identification of noncoding drivers has proven to be challenging73. Yet, noncoding somatic driver 633 
mutations or focal amplications in regulatory regions impacting expression have been reported 634 
for MYC72, TERT73, and KLF531. The observed overlap between GWAS-identified CRC risk loci 635 
and somatic driver regions strongly suggests that expanding the search of somatic driver 636 
mutations to noncoding regulatory elements will yield additional discoveries and that searches 637 
for somatic drivers can be guided by GWAS findings.  638 
 639 
Additionally, we found loci near proposed drug targets, including CHD1, implicated by the rare 640 
variant signal, and KLF5. To date, cancer drug target discovery research has almost exclusively 641 
focused on properties of cancer cells, yielding drugs that target proteins either highly expressed 642 
or expressed in a mutant form due to frequent recurrent somatic missense mutations (e.g., 643 
BRAFV600E) or gene fusion events. In stark contrast with other common complex diseases, cancer 644 
GWAS results are not being used extensively to inform drug target selection. It has been 645 
estimated that selecting targets supported by GWAS could double the success rate in clinical 646 
development81. Our discoveries corroborate that not using GWAS results to inform drug 647 
discovery is a missed opportunity, not only for treating cancers, but also for chemoprevention in 648 
high-risk individuals. 649 
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 650 
In summary, in the largest genome-wide scan for sporadic CRC risk thus far, we identified the 651 
first rare variant signal for sporadic CRC, and almost doubled the number of known association 652 
signals. Our findings provide a substantial number of new leads that may spur downstream 653 
investigation into the biology of CRC risk, and that will impact drug development and clinical 654 
guidelines, such as personalized screening decisions. 655 
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FIGURE LEGENDS 882 
 883 
Figure 1  Conditionally independent association signals at the BMP2 locus. Regional 884 
association plot showing the unconditional –log10(P-value) for the association with CRC risk in 885 
the combined meta-analysis of up to 125,478 individuals, as a function of genomic position 886 
(Build 37) for each variant in the region. The lead variants are indicated by a diamond symbol 887 
and its positions are indicated by dashed vertical lines. The color-labeling and shape of all other 888 
variants indicate the lead variant with which they are in strongest LD. The two new genome-889 
wide significant signals are indicated by an asterisk. 890 
 891 
Figure 2  Functional genomic annotation of new CRC risk locus overlapping KLF5 super-892 
enhancer. Top: Regional association plot showing the unconditional –log10(P-value) for the 893 
association with CRC risk in the combined meta-analysis of up to 125,478 individuals, as a 894 
function of genomic position (Build 37) for each variant in the region. The lead variants are 895 
indicated by a diamond symbol and its positions are indicated by dashed vertical lines. The 896 
color-labeling and shape of all other variants indicate the lead variant with which they are in 897 
strongest LD. Bottom: UCSC genome browser annotations for region overlapping the super-898 
enhancer flanked by KLF5 and KLF12, and spanning variants in LD with rs78341008, and with 899 
two conditionally independent association signals indexed by rs45597035 and rs1924816. The 900 
region is annotated with the following tracks (from top to bottom): UCSC gene annotations; 901 
epigenomic profiles showing MACS2 peak calls as transparent overlays for different samples 902 
taken from non-diseased colonic crypt cells or colon tissue (purple) and from different primary 903 
CRC cell lines or tumor samples (teal); position of the lead variants and variants in LD with the 904 
lead; variants in the 99% credible set; the union of super-enhancers called using the ROSE 905 
package; gray bars highlight the targeted enhancers (e1,e3, and e4) previously shown by Zhang 906 
et al.31 to have combinatorial effects on KLF5 expression. ATAC-seq data newly generated for 907 
this study show high resolution annotation of putative binding regions within the active super-908 
enhancer further fine-mapping putative causal variants at each of the three signals. 909 
 910 
Figure 3  Recommended age to start CRC screening based on a polygenic risk score (PRS). 911 
The PRS was constructed using the 95 known and newly discovered variants. The horizontal 912 
lines represent the recommended age for the first endoscopy for an average-risk person in the 913 
2 
	
current screening guideline for CRC. The risk threshold to determine the age for the first 914 
screening was set as the average of 10-year CRC risks for a 50-year-old man (1.25%) and 915 
woman (0.68%), i.e. (1.25%+0.68%)/2 = 0.97%, who have not previously received an 916 
endoscopy. Details are given in the Online Methods. 917 
 918 
Table 1  New CRC risk loci reaching genome-wide significance (P < 5´10-8) in the combined (Stage 1 and Stage 2) meta-analysis.  919 
       
Stage 1 meta-analysis: 
up to 34,869 cases and 
29,051 controls 
Stage 2 meta-analysis: 
up to 23,262 cases and 
38,296 controls 
Combined meta-analysis: 
up to 58,131 cases and 
67,347 controls 
Locus Nearby gene(s) 
rsID lead 
variant Chr. 
Position 
(Build 37) 
Alleles 
(risk/other) 
RAF 
(%) OR 95% CI P OR 95% CI P OR 95% CI P 
Rare variants 
5q21.1 RGMB; CHD1 rs145364999* 5 98,206,082 T/A 99.69 1.57 1.20-2.05 9.0´10-4 1.93 1.48-2.52 1.0´10-6 1.74 1.45-2.10 6.3´10-9 
Low-frequency variants 
3q13.2 BOC rs72942485 3 112,999,560 G/A 98.02 1.16 1.07-1.26 2.5´10-4 1.23 1.12-1.35 1.5´10-5 1.19 1.12-1.26 2.1´10-8 
Common variants 
1p34.3 FHL3 rs4360494§ 1 38,455,891 G/C 45.39 1.05 1.03-1.08 2.9´10-5 1.06 1.03-1.08 3.3´10-5 1.05 1.04-1.07 3.8´10-9 
1p32.3 TTC22; PCSK9 rs12144319* 1 55,246,035 C/T 25.48 1.07 1.04-1.10 1.4´10
-6 1.07 1.04-1.10 5.5´10-6 1.07 1.05-1.09 3.3´10-11 
2q24.2 MARCH7; TANC1 rs448513
§ 2 159,964,552 C/T 32.60 1.06 1.03-1.08 1.9´10-5 1.05 1.02-1.08 5.8´10-4 1.05 1.03-1.07 4.4´10-8 
2q33.1 SATB2 rs983402* 2 199,781,586 T/C 33.12 1.05 1.03-1.08 7.2´10-5 1.08 1.05-1.11 1.0´10-8 1.07 1.05-1.09 7.7´10-12 
3q22.2 SLCO2A1 rs10049390§ 3 133,701,119 A/G 73.53 1.06 1.03-1.09 4.9´10-5 1.07 1.04-1.10 1.8´10-5 1.06 1.04-1.08 3.8´10-9 
4q24 TET2 rs1391441 4 106,128,760 A/G 67.20 1.05 1.02-1.07 1.5´10-4 1.06 1.03-1.09 2.3´10-5 1.05 1.03-1.07 1.6´10-8 
4q31.21 HHIP rs11727676 4 145,659,064 C/T 9.80 1.08 1.03-1.13 4.5´10-4 1.10 1.05-1.14 1.5´10-5 1.09 1.06-1.12 2.9´10-8 
6p21.32 HLA-DRB1; HLA-DQA1 rs9271695* 6 32,593,080 G/A 79.54 1.09 1.06-1.13 1.3´10
-7 1.09 1.05-1.12 1.7´10-7 1.09 1.07-1.12 1.1´10-13 
7p13 
MYO1G; 
SNHG15; 
CCM2; 
TBRG4 
rs12672022§ 7 45,136,423 T/C 83.45 1.07 1.04-1.11 1.6´10-5 1.06 1.03-1.10 4.4´10-4 1.07 1.04-1.09 2.8´10-8 
9p21.3 
ANRIL; 
CDKN2A; 
CDKN2B 
rs1537372§ 9 22,103,183 G/T 56.92 1.05 1.02-1.07 1.4´10-4 1.06 1.03-1.08 2.4´10-5 1.05 1.03-1.07 1.4´10-8 
9q22.33 GALNT12; TGFBR1 rs34405347
§ 9 101,679,752 T/G 90.34 1.08 1.04-1.13 5.5´10-5 1.09 1.04-1.13 1.5´10-4 1.09 1.05-1.12 3.1´10-8 
9q31.3 LPAR1 rs10980628 9 113,671,403 C/T 21.06 1.05 1.02-1.09 3.1´10-4 1.08 1.05-1.11 1.3´10-6 1.07 1.04-1.09 2.8´10-9 
11q22.1 YAP1 rs2186607 11 101,656,397 T/A 51.78 1.05 1.03-1.08 1.1´10-5 1.05 1.03-1.08 3.3´10-5 1.05 1.04-1.07 1.5´10-9 
12q12 PRICKLE1; YAF2 rs11610543
§ 12 43,134,191 G/A 50.13 1.05 1.03-1.08 1.1´10-5 1.06 1.03-1.08 2.8´10-5 1.05 1.04-1.07 1.3´10-9 
12q13.3 STAT6; LRP1; NAB2 rs4759277 12 57,533,690 A/C 35.46 1.07 1.04-1.09 8.4´10
-7 1.04 1.02-1.07 1.6´10-3 1.05 1.04-1.07 9.4´10-9 
13q13.3 SMAD9 rs7333607* 13 37,462,010 G/A 23.50 1.09 1.06-1.12 2.5´10-8 1.07 1.04-1.10 4.4´10-6 1.08 1.06-1.10 6.3´10-13 
13q22.1 KLF5 rs78341008§ 13 73,791,554 C/T 7.19 1.13 1.07-1.18 1.4´10-6 1.11 1.05-1.16 4.8´10-5 1.12 1.08-1.16 3.2´10-10 
13q34 
COL4A2; 
COL4A1; 
RAB20 
rs8000189 13 111,075,881 T/C 64.01 1.05 1.02-1.07 2.1´10-4 1.07 1.04-1.10 1.3´10-6 1.06 1.04-1.08 1.8´10-9 
14q23.1 DACT1 rs17094983§ 14 59,189,361 G/A 87.73 1.10 1.07-1.15 8.4´10-8 1.08 1.04-1.12 9.0´10-5 1.09 1.06-1.12 4.6´10-11 
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15q22.33 SMAD3 rs56324967* 15 67,402,824 C/T 67.57 1.07 1.04-1.10 2.2´10-7 1.08 1.05-1.11 9.8´10-8 1.07 1.05-1.09 1.1´10-13 
16q23.2 MAF rs9930005§ 16 80,043,258 C/A 43.03 1.05 1.03-1.08 1.3´10-5 1.05 1.02-1.07 4.0´10-4 1.05 1.03-1.07 2.1´10-8 
17p12 LINC00675 rs1078643* 17 10,707,241 A/G 76.36 1.07 1.04-1.10 9.2´10-6 1.09 1.05-1.12 1.1´10-7 1.08 1.05-1.10 6.6´10-12 
17q24.3 LINC00673 rs983318§ 17 70,413,253 A/G 25.26 1.07 1.04-1.10 1.2´10-6 1.05 1.02-1.08 8.0´10-4 1.06 1.04-1.08 5.6´10-9 
17q25.3 RAB40B; METRLN rs75954926* 17 81,061,048 G/A 65.68 1.10 1.07-1.13 9.4´10
-11 1.09 1.06-1.12 4.8´10-9 1.09 1.07-1.11 3.0´10-18 
19p13.11 KLF2 rs34797592§ 19 16,417,198 T/C 11.82 1.09 1.05-1.13 8.2´10-6 1.09 1.05-1.13 1.2´10-5 1.09 1.06-1.12 4.2´10-10 
19q13.43 TRIM28 rs73068325 19 59,079,096 T/C 18.26 1.06 1.03-1.09 2.1´10-4 1.07 1.04-1.11 5.0´10-5 1.07 1.04-1.09 4.2´10-8 
20q13.12 TOX2;  HNF4A rs6031311§ 20 42,666,475 T/C 75.91 1.07 1.04-1.10 1.7´10
-6 1.05 1.02-1.08 7.6´10-4 1.06 1.04-1.08 6.8´10-9 
20q13.33 TNFRSF6B; RTEL1 rs2738783
§,¶ 20 62,308,612 T/G 20.29 1.07 1.04-1.10 2.6´10-6 1.05 1.02-1.08 3.3´10-3 1.06 1.04-1.08 5.3´10-8 
Lead variant is the most associated variant at the locus. rsIDs based on NCBI dbSNP Build 150. Alleles are on the + strand. Chr.: Chromosome. RAF: Risk allele frequency, based 920 
on stage 2 data. OR, odds ratio estimate for the risk allele. All P-values reported in this table are based on fixed-effects inverse variance-weighted meta-analysis. 921 
*Indicates that variant or LD proxy (r2>0.7) was selected for our custom genotyping panel and formally replicates in the Stage 2 meta-analysis at a Bonferroni significance 922 
threshold of P < 7.8×10-6. 923 
§Indicates that variant or LD proxy (r2>0.7) was selected for our custom genotyping panel but did not attain Bonferroni significance in the Stage 2 meta-analysis. 924 
¶This SNP reached genome-wide significance in the combined (Stage 1 + Stage 2) sample-size weighted meta-analysis based on likelihood ratio test results (P = 4.9´10-8). 925 
 926 
 927 
 928 
 929 
 930 
 931 
 932 
 933 
 934 
 935 
 936 
 937 
 938 
 939 
 940 
 941 
 942 
 943 
 944 
 945 
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Table 2  Additional new conditionally independent association signals at known and newly identified CRC risk loci that reach genome-wide 946 
significance (P < 5´10-8) in the combined meta-analysis of up to 125,478 individuals. 947 
          Joint multiple-variant analysis 
Locus Nearby gene(s) 
rsID lead 
variant Chr. 
Position 
(Build 37) 
Alleles 
(risk/other) 
RAF 
(%) ORunconditional 95% CI Punconditional 
Conditioning 
variant(s) ORconditional 95% CI Pconditional 
Low-frequency variants 
11q13.4 POLD3 rs61389091 11 74,427,921 C/T 96.06 1.23 1.18-1.29 1.2´10-18 rs7121958*, 
rs7946853 
1.21 1.16-1.27 3.7´10-16 
Common variants 
2q33.1 SATB2 rs11884596 2 199,612,407 C/T 38.23 1.06 1.04-1.08 1.1´10-9 rs983402 1.06 1.04-1.07 3.6´10-9 
5p15.33 TERT; 
CLPTM1L 
rs78368589 5 1,240,204 T/C 5.97 1.14 1.10-1.18 9.4´10-12 rs2735940* 1.12 1.08-1.16 4.1´10-9 
5p13.1 LINC00603; 
PTGER4 
rs7708610 5 40,102,443 A/G 35.64 1.04 1.02-1.06 1.5´10-5 rs12514517* 1.06 1.04-1.08 3.8´10-9 
6p21.32 HLA-B; 
MICA; 
MICB; 
NFKBIL1; 
TNF 
rs2516420 6 31,449,620 C/T 92.63 1.10 1.06-1.13 1.3´10-7 rs9271695, 
rs116685461, 
rs116353863 
1.12 1.08-1.16 2.0´10-10 
8q24.21 MYC rs4313119 8 128,571,855 G/T 74.86 1.06 1.04-1.08 1.0´10-9 rs6983267*, 
rs7013278 
1.06 1.04-1.08 2.1´10-9 
12p13.32 CCND2 rs3217874 12 4,400,808 T/C 42.82 1.08 1.06-1.10 1.2´10-17 rs3217810*, 
rs35808169* 
1.06 1.04-1.08 2.4´10-9 
15q13.3 GREM1 rs17816465 15 33,156,386 A/G 20.55 1.07 1.04-1.09 6.8´10-9 rs2293581*, 
rs12708491* 
1.07 1.05-1.10 1.4´10-10 
20p12.3 BMP2 rs28488 20 6,762,221 T/C 63.88 1.06 1.04-1.08 2.6´10-11 rs189583*, 
rs4813802*, 
rs994308 
1.07 1.05-1.09 2.6´10-14 
20p12.3 BMP2 rs994308 20 6,603,622 C/T 59.39 1.08 1.06-1.10 4.8´10-18 rs189583*, 
rs4813802*, 
rs28488 
1.06 1.05-1.08 8.6´10-12 
Lead variant is the most associated variant at the locus in the conditional analysis. rsIDs based on NCBI dbSNP Build 150. Alleles are on the + strand. Chr.: Chromosome. RAF: 948 
Risk allele frequency, based on stage 2 data. OR, odds ratio estimates are for the risk allele. Conditioning variants are the lead variant of other conditionally independent 949 
association signals with P < 1´10-5 within 1-Mb of the new association signal. Because of extensive LD we used a 2-Mb distance for the MHC region (6p21.32). All lead variants 950 
for the new association signals are in linkage equilibrium with any previously reported CRC risk variants at the locus (r2 <0.10).  951 
*Indicates that the conditioning variant is either the index variant, or a variant in LD with the index variant reported in previous GWAS. Details and full results are provided in 952 
Supplementary Table 5. 953 
 954 
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ONLINE METHODS 955 
Study samples. 956 
After quality control (QC), this study included whole-genome sequencing (WGS) data for 1,439 957 
colorectal cancer (CRC) cases and 720 controls from 5 studies, and GWAS array data for 58,131 958 
CRC or advanced adenoma cases (3,674; 6.3% of cases) and 67,347 controls from 45 studies 959 
from GECCO, CORECT, and CCFR. The Stage 1 meta-analysis comprised existing genotyping 960 
data from 30 studies that were included in previously published CRC GWAS13,18,22. After QC, 961 
the Stage 1 meta-analysis included 34,869 cases and 29,051 controls. Study participants were 962 
predominantly of European ancestry (31,843 cases and 26,783 controls; 91.7% of participants). 963 
Because it was shown previously that the vast majority of known CRC risk variants are shared 964 
between Europeans and East Asians17, we included 3,026 cases and 2,268 controls of East Asian 965 
ancestry to increase power for discovery. The Stage 2 meta-analysis comprised newly generated 966 
genotype data involving 4 genotyping projects and 22 studies. After QC, the Stage 2 meta-967 
analysis included 23,262 cases and 38,296 controls, all of European ancestry. Studies, sample 968 
selection, and matching are described in the Supplementary Text. Supplementary Table 1 969 
provides details on sample numbers, and demographic characteristics of study participants. All 970 
participants provided written informed consent, and each study was approved by the relevant 971 
research ethics committee or institutional review board. Four normal colon mucosa biopsies for 972 
ATAC-seq were obtained from patients with a normal colon at colonoscopy at the Institut 973 
d’Investigació Biomèdica de Bellvitge (IDIBELL), Spain. Patients signed informed consent, and 974 
the protocol was approved by the Bellvitge Hospital Ethics Committee (Colscreen protocol 975 
PR084/16). 976 
 977 
Whole-genome sequencing. 978 
We performed low-pass WGS of 2,192 samples from 5 studies at the University of Washington 979 
Northwest Genomics Center (Seattle, WA, USA). Cases and controls were processed and 980 
sequenced together. Libraries were prepared with ThruPLEX DNA-seq kits (Rubicon Genomics) 981 
and paired-end sequencing performed using Illumina HiSeq 2500 sequencers. Reads were 982 
mapped to human reference genome (GRCh37 assembly) using Burrows-Wheeler aligner BWA 983 
v0.6.282. Fold genomic coverage averaged 5.3× (range: 3.8-8.6×). We used the GotCloud 984 
population-based multi-sample variant calling pipeline83 for post-processing of BAM files with 985 
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initial alignments, and to detect and call single nucleotide variants (SNVs) and short insertions 986 
and deletions (indels). After removing duplicated reads and recalibrating base quality scores, QC 987 
checks included sample contamination detection. Variants were jointly called across all samples. 988 
To identify high-quality sites, the GotCloud pipeline performs a two-step filtering process. First, 989 
lower quality variants are identified by applying individual variant quality statistic filters. Next, 990 
variants failing multiple filters are used as negative examples to train a support vector machine 991 
(SVM) classifier. Finally, we performed a haplotype-aware genotype refinement step via 992 
Beagle84 and ThunderVCF85 on the SVM-filtered VCF files. After further sample QC, we 993 
excluded samples with estimated DNA contamination >3% (16), duplicated samples (5) or 994 
related individuals (1), sex discrepancies (0), and samples with low concordance with GWAS 995 
array data (11). We checked for ancestry outliers by performing principal components analysis 996 
(PCA) after merging in data for shared, linkage disequilibrium (LD)-pruned SNVs for 1,092 997 
individuals from the 1000 Genomes Project86. After QC, sequences were available for 1,439 998 
CRC cases and 720 controls of European ancestry. 999 
 1000 
GWAS genotype data and quality control. 1001 
Details of genotyping and QC for studies included in the Stage 1 meta-analysis are described 1002 
elsewhere13,18,22. Supplementary Table 1 provides details of genotyping platforms used. Before 1003 
association analysis, we pooled individual-level genotype data of all Stage 1 studies for a subset 1004 
of SNPs to enable identification of unexpected duplicates and close relatives. We calculated 1005 
identity by descent (IBD) for each pair of samples using KING-robust87 and excluded duplicates 1006 
and individuals that are second-degree or more closely related. As part of Stage 2, 28,805 1007 
individuals from 19 studies were newly genotyped on a custom Illumina array based on the 1008 
Infinium OncoArray-500K26 and a panel of 15,802 successfully manufactured custom variants 1009 
(described in Supplementary Text). An additional 8,725 individuals from 5 studies were 1010 
genotyped on the Illumina HumanOmniExpressExome-8v1-2 array. Genotyping and calling for 1011 
both projects were performed at the Center for Inherited Disease Research (CIDR) at Johns 1012 
Hopkins University. Genotypic data that passed initial QC at CIDR subsequently underwent QC 1013 
at the University of Washington Genetic Analysis Center (UW GAC) using standardized 1014 
methods detailed in Laurie et al.88. The median call rate for the custom Infinium OncoArray-1015 
500K data was 99.97%, and error rate estimated from 301 sample duplicate pairs was 9.99e-7. A 1016 
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relatively low number of samples (246) had a missing call rate >2%, with the highest being 1017 
3.48%, and were included in analysis. For the HumanOmniExpressExome-8v1-2 data, median 1018 
call rate was 99.96%, and the error rate estimated from 179 sample duplicate pairs was 2.65e-6. 1019 
Thirty samples had a missing call rate >2%, with the highest being 3.79%, and were included in 1020 
analysis. We excluded samples with discrepancies between reported and genotypic sex based on 1021 
X chromosome heterozygosity and the means of sex chromosome probe intensities, unintentional 1022 
duplicates, and close relatives defined as individuals that are second-degree or more closely 1023 
related. After further excluding individuals of non-European ancestry as determined by PCA (see 1024 
below), the custom OncoArray data included in analysis comprised 11,852 CRC cases and 1025 
11,895 controls, and the HumanOmniExpressExome-8v1-2 array data included in analysis 1026 
comprised 4,439 CRC cases and 4,115 controls. Only variants passing QC were used for 1027 
imputation. We excluded variants failing CIDR technical filters or UW GAC quality filters, 1028 
which included missing call rate >2%, discordant calls in sample duplicates, and departures from 1029 
Hardy-Weinberg equilibrium (HWE) (P <1e-4) based on European-ancestry controls. The Stage 1030 
2 analysis also included genotype data from the CORSA study (Supplementary Text). In total, 1031 
2,354 individuals were genotyped using the Affymetrix Axiom Genome-Wide Human CEU 1 1032 
Array. We called genotypes using the AxiomGT1 algorithm. All samples had missing call rate 1033 
<3%. We excluded samples with discrepancies between reported and genotypic sex (20), close 1034 
relatives defined as individuals that are second-degree or more closely related (94), as inferred 1035 
using KING-robust87, and individuals of non-European ancestry (6) as inferred from PCA. After 1036 
QC, data included in analysis comprised 1,460 cases and 774 controls. Prior to phasing and 1037 
imputation, we filtered out SNPs with missing call rate >2%, or HWE P <1e-4. Imputed 1038 
genotype data were obtained from UK Biobank and QC and imputation are described 1039 
elsewhere89. A nested case-control dataset was constructed as described in the Supplementary 1040 
Text. We excluded individuals of non-European ancestry as inferred from PCA, and randomly 1041 
dropped one individual from each pair that were more closely related than third-degree relatives 1042 
as inferred using KING-robust. This resulted in excluding 137 samples. In total, 5,356 CRC 1043 
(5,004) or advanced adenoma (352) cases and 21,407 matched controls were included in the 1044 
replication analysis. 1045 
 1046 
Principal components analysis. 1047 
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After excluding close relatives, we performed PCA using PLINK1.990 on LD-pruned sets of 1048 
autosomal SNPs obtained by removing regions with extensive long-range LD91,92, SNPs with 1049 
minor allele frequency (MAF) <5%, or HWE P <1e-4, or any missingness, and carrying out LD 1050 
pruning using the PLINK option ‘-indep-pairwise 50 5 0.2’. To identify population outliers we 1051 
merged in 1,092 individuals from 1000 Genomes Project Phase III and performed PCA using the 1052 
intersection of variants93. 1053 
 1054 
Genotype imputation. 1055 
The 2,159 whole-genome sequences described above were used to create a phased imputation 1056 
reference panel. After estimating haplotypes for all GWAS array data sets using SHAPEIT294, 1057 
we used minimac395 to impute from this reference panel (19.6 million variants with minor allele 1058 
count (MAC) >1) into the GWAS datasets described above. We also imputed to the Haplotype 1059 
Reference Consortium (HRC) panel25 (39.2 million variants) using the University of Michigan 1060 
Imputation Server95. To improve imputation accuracy for Stage 1 data sets, phasing and 1061 
imputation were performed after pooling studies/genotype projects that used the same, or very 1062 
similar, genotyping platforms (Supplementary Table 1). For Stage 2, we performed phasing 1063 
and imputation separately for each genotyping project data set and imputed to the HCR panel. 1064 
 1065 
Statistical analyses. 1066 
Association testing of sequence data. 1067 
We tested variants with MAC ≥5 for CRC association using Firth’s bias-reduced logistic 1068 
regression as implemented in EPACTS (genome.sph.umich.edu/wiki/EPACTS) and adjusted for 1069 
sex, age, study, and 3 principal components (PCs) calculated from an LD-pruned set of 1070 
genotypes. We performed rare variant aggregate tests at the gene and enhancer level using the 1071 
Mixed effects Score Test (MiST)96. This unified test is a linear combination between 1072 
unidirectional burden and bidirectional variance component tests that performs best in terms of 1073 
statistical power across a range of architectures97. 1074 
 1075 
Association and meta-analysis. 1076 
Stage 1 comprised two large mega-analyses of pooled individual-level genotype data sets 1077 
(Supplementary Table 12). The four Stage 2 genotyping project data sets were analyzed 1078 
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separately. Within each data set, variants with an imputation accuracy r2 ≥0.3 and MAC ≥50 1079 
were tested for CRC association using the imputed genotype dosage in a logistic regression 1080 
model adjusted for age, sex, and study/genotyping project-specific covariates, including PCs to 1081 
adjust for population structure (Supplementary Table 12). To account for residual confounding 1082 
within CORSA, we tested association with each variant using a linear mixed model and kinship 1083 
matrix calculated from the data, as implemented in EMMAX98. To enable meta-analysis, we then 1084 
calculated approximate allelic log odds ratios (OR) and corresponding standard errors as 1085 
described in Cook et al.99. 1086 
Next, we combined association summary statistics across analyses via fixed-effects inverse 1087 
variance-weighted meta-analysis. Because Wald tests can be notably anti-conservative for rare 1088 
variant associations, we also performed likelihood ratio-based tests, followed by sample-size 1089 
weighted meta-analysis, as implemented in METAL100. In total, 16,900,397 variants were 1090 
analyzed. To examine residual population stratification, we inspected quantile-quantile plots of 1091 
test statistics (Supplementary Figure 8), and calculated genomic control inflation statistics 1092 
(λGC). λGC for the combined meta-analysis was 1.105, and for Stage 1 and 2 meta-analyses was 1093 
1.071 and 1.075, respectively. Because λGC increases with sample size for polygenic phenotypes, 1094 
even in the absence of confounding biases101, we investigated the effect of confounding due to 1095 
residual population stratification using LD score regression102. Because of limitations of LD 1096 
score regression, this analysis is restricted to common variants (MAF≥1%) for which λGC was 1097 
1.188 in the combined meta-analysis. The LD score regression intercept was 1.067, which is 1098 
substantially less than λGC, indicating at most a small contribution of bias and that inflation in χ2 1099 
statistics results mostly from polygenicity. We also calculated λ1,000 which is the equivalent 1100 
inflation statistic for a study with 1,000 cases and 1,000 controls103. For the combined meta-1101 
analysis, λ1000 was 1.004 and for both Stage 1 and 2 meta-analyses this was 1.003. 1102 
 1103 
Significance threshold for the replication genotyping experiment. 1104 
To protect against probe design failure, we built redundancy into the custom genotyping panel by 1105 
including LD proxies of independently associated variants selected for follow-up. To determine 1106 
the number of independent tests, we performed LD clumping of the 9,198 analyzed variants that 1107 
were selected for replication genotyping based on the Stage 1 meta-analysis, and that survived 1108 
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filters described above. Using an r2 threshold of 0.1 this translated to 6,438 independent tests and 1109 
a Bonferroni significance threshold of 0.05/6,438=7.8×10-6. 1110 
 1111 
Conditional and joint multiple-variant analysis. 1112 
To identify additional distinct association signals at CRC loci, we performed a series of 1113 
conditional meta-analyses. At each locus attaining P <5×10-8, we included the genotype dosage 1114 
for the variant showing the strongest statistical evidence for association in the region in the 1115 
combined meta-analysis, as an additional covariate in the respective logistic regression models. 1116 
Association summary statistics for each variant in the region were then combined across studies 1117 
by a fixed-effects meta-analysis. If at least one association signal attained a significance level of 1118 
P <1×10-5 in this meta-analysis, we performed a second round of conditional meta-analysis, 1119 
adding the variant showing the strongest statistical evidence for association in the region in the 1120 
first round of conditional meta-analysis as a covariate to the logistic regression models used in 1121 
the first round. We repeated this procedure and kept adding variants to the model until no 1122 
additional variants at the locus attained P <1×10-5. Finally, we performed a joint multiple-variant 1123 
analysis in which we jointly estimated the effects of variants selected in each step and tested for 1124 
each variant whether the P-value from the joint multiple-variant analysis (PJ) was <1×10-5. 1125 
Analyses were performed on 2-Mb windows centered on the most associated variant in the 1126 
unconditional analysis. If windows overlapped, we performed the analysis on the collapsed 1127 
genomic region. Because of extensive LD, we used a 4-Mb window for the MHC region. 1128 
 1129 
Definition of known loci. 1130 
We compiled a list of 62 previously reported genome-wide significant CRC association signals 1131 
from the literature (Supplementary Table 3). Because of improved power and coverage of our 1132 
study, we identified the most associated variant at each signal, and used these lead variants for 1133 
further analyses, rather than the previously reported index variant. 1134 
 1135 
Refinement of association signals. 1136 
To refine new association signals, we constructed credible sets that were 99% likely, based on 1137 
posterior probability, to contain the causal disease-associated SNP104. In brief, for each distinct 1138 
signal, we retained a candidate set of variants by identifying all analyzed variants with r2 ≥0.1 1139 
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with the most associated variant within a 2-Mb window centered on the most associated variant. 1140 
We calculated approximate Bayes’ factors (ABF)105 for each variant as: 1141 
 1142 !"# = 1 − '	)*+,/.	1143 
 1144 
where r = 0.04/(s.e.2+0.04), z = β/s.e., and β and s.e. are the log OR estimate and its standard 1145 
error from the combined meta-analysis. For loci with multiple distinct signals, results are based 1146 
on conditional meta-analysis, adjusting for all other index variants in the region. We then 1147 
calculated the posterior probability of being causal as ABF/T where T is the sum of ABF values 1148 
over all candidate variants. Next, variants were ranked in decreasing order by posterior 1149 
probabilities and the 99% credible set was obtained by including variants with the highest 1150 
posterior probabilities until the cumulative posterior probability ≥99%. 1151 
 1152 
Functional genomic annotation. 1153 
To nominate variants for future laboratory follow-up, we performed bioinformatic analysis at 1154 
each new signal using our functional annotation database, and a custom UCSC analysis data hub. 1155 
Using ANNOVAR106, we annotated lead variants and variants in LD (r2 ≥0.4) with the lead 1156 
variant, relative to features pertaining to i) gene-centric function (PolyPhen2107), ii) genome-1157 
wide functional prediction scores (CADD108, DANN109, EigenPC110), iii) disease relatedness 1158 
(GWAS catalog46), and iv) CRC-relevant regulatory functions (enhancer, repressor, DNA 1159 
accessible, and transcription factor binding site (TFBS)111,112; Supplementary Table 13). 1160 
Supplementary Table 8 summarizes variant annotations relative to the CCDS Project113, and 1161 
reference genome GRCh37. Variants were maintained in Supplementary Table 8 if they met 1162 
any of the following conditions: DANN score ≥0.9, CADD phred score ≥20, Eigen-PC phred 1163 
score ≥17, PolyPhen2 “probably damaging”, “stop loss”, “stop gain”, “splicing”, or were 1164 
positioned in a predicted regulatory element. We visually inspected loci overlapping with CRC-1165 
relevant functional genomic annotations. Variants positioned in enhancers with aberrant CRC 1166 
activity were identified by comparing epigenomes of non-diseased colorectal tissues/colonic 1167 
crypt cells to epigenomes of primary CRC cell lines (data accessible at NCBI GEO database, 1168 
accession GSE77737). We prioritized target genes for loci with predicted regulatory function. 1169 
Evidence suggests that Topological Association Domains (TADs) can be used to map physical 1170 
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boundaries on gene promoter interactions with distal regulatory elements114–116. As such, we used 1171 
GMI12878 Hi-C Chromosome Conformation Capture data to identify gene promoters that were 1172 
in the same TADs as risk loci using the WashU Epigenome Browser 1173 
(https://epigenomegateway.wustl.edu/). Genes in this list were further prioritized based on 1174 
biological relevancy and expression quantitative trait loci (eQTL) data from Genotype-Tissue 1175 
Expression (GTEx)117 using HaploReg v4.1118. 1176 
 1177 
ATAC-seq assay. 1178 
We generated high resolution maps of DNA accessible regions in normal colon mucosa samples 1179 
using the Assay for Transposase-Accessible Chromatin using sequencing (ATAC-seq). Using the 1180 
updated omni-ATAC protocol for archival samples, we performed ATAC-seq in four colon 1181 
mucosa biopsies from the ICO-biobank taken from participants undergoing screening at 1182 
IDIBELL, Spain. Biopsies were cryopreserved by slow freezing using a solution of 10% DMSO, 1183 
90% media, and Mr. Frosty Cryo 1°C Freezing Containers (Thermo Scientific). ATAC-seq was 1184 
implemented as prescribed with two exceptions. Instead of dounce homogenizer we used a tissue 1185 
lyser and stainless bead system, pulverizing at 40Hz for 2 mins and pulsing at 50Hz for 10-20 1186 
seconds. Secondly, Illumina library quantification was performed using picogreen quantitation 1187 
and TapeStation instead of KAPA quantitative qPCR. Libraries were sequenced to an average of 1188 
25M paired end reads using Illumina HiSeq 2500. The ENCODE data processing pipeline was 1189 
implemented (https://github.com/kundajelab/atac_dnase_pipelines) aligning to hg19119. QC 1190 
results are summarized in Supplementary Table 14. 1191 
 1192 
Regulatory and functional information enrichment analysis. 1193 
We used GARFIELD74 to identify cell types, tissues, and functional genomic features relevant to 1194 
CRC risk. This method tests for enrichment of association in features primarily extracted from 1195 
ENCODE and Roadmap Epigenomics Project data, while accounting for sources of confounding, 1196 
including LD. We applied default settings and used the author-supplied data which is suitable for 1197 
analysis of GWAS results based on European-ancestry individuals. 1198 
 1199 
Pathway and gene set enrichment analysis. 1200 
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We used MAGENTA to test predefined gene sets (e.g., KEGG pathways) for enrichment for 1201 
CRC risk associations75. We used combined meta-analysis results as input and applied default 1202 
settings which included removing genes that fall in the MHC region from analysis. Enrichment 1203 
was tested at two gene P-value cutoffs: 95th and 75th percentiles of all gene P-values in the 1204 
genome. 1205 
 1206 
Estimation of contribution of rare variants to heritability. 1207 
We used the LD- and MAF-stratified component GREML (GREML-LDMS) method as 1208 
implemented in GCTA76 to estimate the proportion of variation in liability for CRC explained by 1209 
all imputed autosomal variants (i.e., estimate of narrow-sense heritability ℎ0.), and the proportion 1210 
contributed by rare variants (MAF ≤1%). Because of computational limitations we analyzed a 1211 
subset of 11,895 cases and 14,659 controls imputed to our WGS panel. We analyzed individual-1212 
level data for 17,649,167 imputed variants with MAC >3 and HWE test P ≥10-6. Following Yang 1213 
et al.76, we did not filter on imputation quality. In brief, we stratified variants into groups based 1214 
on MAF (boundaries at 0.001, 0.01, 0.1, 0.2, 0.3, 0.4) and mean LD score (boundaries at 1215 
quartiles) calculated as described in Yang et al.76. We then calculated genetic relationship 1216 
matrices (GRMs) for each of these 28 variant partitions and jointly estimated variance 1217 
components for these partitions, adjusting for age, sex, study, genotyping batch, and three 1218 
genotype PCs. From the variance component estimates and their variance-covariance matrix we 1219 
estimated the contribution of rare variants (MAF ≤1%) and common variants (MAF >1%), and 1220 
calculated standard errors using the delta method. We tested significance of the contribution of 1221 
rare variants using a likelihood ratio test. To calculate heritability on the underlying liability 1222 
scale we interpreted K as lifetime risk120 and used an estimate of 4.3% (Surveillance, 1223 
Epidemiology, and End Results Program (SEER) Cancer Statistics, 2011-2013). 1224 
 1225 
Familial relative risk explained by genetic variants. 1226 
We assumed a multiplicative model within and between variants and calculated the proportion of 1227 
familial relative risk (RR) explained by a given set of genetic variants as  123	45	5123	46	 , where 78	is the 1228 
overall familial RR to first-degree relatives of cases. 79 is the familial RR due to variant : 1229 
calculated as 79 = ;5*5,<=5(;5*5<=5),, where @9	is the risk allele frequency for variant :, A9 = 1 − @9, and '9 1230 
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is the estimated per allele OR9,121. We adjusted the OR estimates of new association signals for 1231 
winner’s curse following Zhong and Prentice78. We represented previously identified association 1232 
signals by the variant showing the strongest statistical evidence of association in the combined 1233 
meta-analysis, and assumed that winner’s curse was negligible. We assumed 78	to be 2.2122. 1234 
Using the delta method, we computed the variance for the proportion of familial RR as follows: 1235 
 1236 CD'('9)9 [ 1FGH	78	 179 2@9A9('9 − 1)(@9'9 + A9)K ].. 1237 
 1238 
Absolute risk of CRC incidence and starting age of first screening. 1239 
We constructed a polygenic risk score (PRS) as a weighted sum of expected risk allele frequency 1240 
for common genetic variants, using the per allele OR for each variant as weights. OR estimates 1241 
for newly discovered variants were adjusted for winner’s curse to avoid potential inflation78. 1242 
Assuming all genetic variants are independent, let N denote a PRS constructed based on K 1243 
variants: N = OPQ9R9ST , where OP	DUV	Q9	are the estimated OR and the number of risk alleles for 1244 
variant i. We assumed N	follows a normal distribution W(X, Y.), where the estimates of mean 1245 
and variance are computed as following: 1246 
X = OP×2×@PR9ST and	Y. = OP.×2×@P×(1 − @P)R9ST , 1247 
where  @P	is the risk allele frequency for variant : = 1,⋯ , _. Then the baseline hazard at each 1248 
age `, 78(`), is computed as following: 1249 78(1) = 7∗(1) b(c) Vc)d b(c)Vc 1250 78(`) = 7∗(`) )c@	(− 78(:)efT9ST )d) b(c)Vc)c@	(− 78(:)efT9ST )d) )db(c)Vc 	for	` = 2,⋯ ,100, 1251 
and 7∗(`) are the incidence rates for non-Hispanic whites who have not taken an endoscopy 1252 
before, derived from population incidence rates during 1992-2005 from the SEER Registry. 1253 
Using these baseline hazard rates, we estimated the 10-year absolute risk of developing CRC 1254 
given age and a PRS as previously described123. By setting a risk threshold as the average of the 1255 
10-year CRC risk for a 50-year old man (1.25%) and woman (0.68%), i.e., 1256 
(1.25%+0.68%)/2=0.97%, who have not previously received an endoscopy124, we estimated the 1257 
11 
	
recommended starting age of first screening given the PRS. Variants and OR estimates used in 1258 
these analyses are given in Supplementary Table 15. 1259 
 1260 
Data availability. 1261 
All whole-genome sequence data have been deposited at the database of Genotypes and 1262 
Phenotypes (dbGaP), which is hosted by the U.S. National Center for Biotechnology Information 1263 
(NCBI), under accession number phs001554.v1.p1. All custom Infinium OncoArray-500K array 1264 
data for the studies in the Stage 2 meta-analysis have been deposited at dbGaP under accession 1265 
number phs001415.v1.p1. All Illumina HumanOmniExpressExome-8v1-2 array data for the 1266 
studies in the Stage 2 meta-analysis have been deposited at dbGaP under accession number 1267 
phs001315.v1.p1. Genotype data for the studies included in the Stage 1 meta-analysis have been 1268 
deposited at dbGaP under accession number phs001078.v1.p1. The UK Biobank resource was 1269 
accessed through application number 8614. 1270 
 1271 
Reporting Summary. 1272 
Further information on experimental design is available in the Life Sciences Reporting Summary 1273 
linked to this article. 1274 
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